Dealing with premature menopause in women at high-risk for hereditary genital and breast cancer

Minerva Ginecologica

Volumn 68, Issue 5, 2016, Pages 602-612

  Nappi, Rossella E ^a,b   Cassani, Chiara ^a   Rossi, Margherita ^a   Zanellini, Francesca ^a   Spinillo, Arsenio ^a,b  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

BRCA1 gene; BRCA2 gene; Hormone replacement therapy; Ovariectomy; Premature menopause; Prophylactic surgical procedures

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN;

BONE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RISK; CANCER THERAPY; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); COGNITION; EARLY MENOPAUSE; FAMILIAL CANCER; FEMALE; FEMALE GENITAL TRACT CANCER; HIGH RISK PATIENT; HUMAN; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEXUAL HEALTH; SEXUAL WELL BEING; WELLBEING; BREAST TUMOR; ESTROGEN THERAPY; GENETICS; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; PHYSIOLOGY; PROCEDURES; SALPINGECTOMY;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; MENOPAUSE, PREMATURE; MUTATION; OVARIAN NEOPLASMS; OVARIECTOMY; QUALITY OF LIFE; SALPINGECTOMY;

EID: 84983652644     PISSN: 00264784     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Chen S, Parmigiani G. Meta-analysis of BRCAl and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.
2. Marchetti C, De Felice F, Palaia I, Perniola G, Musella A, Musio D, et al. Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all-cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health 2014;14:150.
3. ®) - Genetic/familial high-risk assessment: breast and ovarian. Version 2.2015 [Internet]. Available from: www.consensocancermamario.com/guias/NCCN-Riesgo-para-Cancer-de-mama-y-de-ovario-2015.pdf [cited 2016 Mar. 14].
4. Rebbeck TL, Kauff RD, Domchek SM. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCAl or BRCA2 mutation carriers. J Natl Cancer Inst 2009;101:80-7.
5. Heemskerk-Gerritsen BA, Seynaeve C, van Asperen CJ, Ausems MG, Collée JM, van Doom HC, et al. Breast cancer risk after salpingo-oophorectomy in healthy BRCA1/2 mutation carriers: revisiting the evidence for risk reduction. J Natl Cancer Inst 2015;107(5).
6. Sismondi P, D'Alonzo M, Pecchio S, Bounous VE, Robba E, Biglia N. Chemoprevention or mastectomy for women at high risk of developing breast cancer. Maturitas 2015;82:271-3.
7. Gadducci A, Biglia, N, Cosio S, Sismondi P, Genazzani R. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophprectomy and hormone replacement therapy. Gynecol Endocrinol 2010;26:568-77.
8. Schenberg T, Mitchell G. Prophylactic bilateral salpingectomy as a prevention strategy in women at high risk of ovarian cancer: a mini review. Front Oncol 2014;4:21.
9. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer - a proposed unifying theory. Am J Surg Pathol 2010;34:433-43.
10. Harmsen MG, Arts-de Jong M, Hoogerbrugge N, Maas AHEM, Prins JB, Bulten J, et al. Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingooophorectomy in BRCA1/2 mutation carriers. BMC Cancer 2015;15:593.
11. Finch A, Valentini A, Greenblatt E, Lynch HT, Ghadirian P, Armel S, et al. Frequency of premature menopause in women who carry a BRCAl or BRCA2 mutation. Fertil Steril 2013;99:1724-8.
12. Wang ET, Pisarska MD, Bresee C, Ida Chen Y-D, Lester J, Afshar Y, et al. BRCAl germline mutations may be associated with reduced ovarian reserve. Fert Steril 2014;102:1723-8.
13. Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Longterm health consequences of premature or early menopause and considerations for management. Climacteric 2015;18:483-91.
14. Gallicchio L, Whiteman MK, Tomic D, Miller KP, Langenberg P, Flaws JA. Type of menopause, patterns of hormone therapy use, and hot flashes. Fertil Steril 2006;85:1432-40.
15. Bhattacharya SM, Jha A. A comparison of health-related quality of life (HRQOL) after natural and surgical menopause. Maturitas 2010;66:431-4.
16. Wild R. Introduction to special issue on surgical menopause. Menopause 2007;14:556-61.
17. Nappi RE, Wawra K, Schmitt S. Hypoactive sexual desire disorder in postmenopausal women. Gynecol Endocrinol 2006;22:318-23.
18. Elit L, Esplen MJ, Butler K, Narod S. Quality of life and psychosexual adjustment after prophylactic oophorectomy for a family history of ovarian cancer. Fam Cancer 2001;1:149-56.
19. Robson M, Hensley M, Barakat R, Brown C, Chi D, Poynor E, et al. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol 2003;89:281-7.
20. Madalinska JB, Hollenstein J, Bleiker E, van Beurden M, Valdimarsdottir HB, Massuger LF, et al. Qualityof-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer. J Clin Oncol 2005;23:6890-8.
21. Kurian AW. Sigal BM. Plevritis SK. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol 2010;28:222-31.
22. Madalinska JB, van Beurden M, Bleiker EM, Valdimarsdottir HB, Hollenstein J Massuger LF, et al. The impact of hormone replacement therapy on menopausal symptoms in younger high-risk women after prophylactic salpingo-oophorectomy. J Clin Oncol 2006;24:3576-82.
23. Johansen N, Liavaag AH, Tanbo TG, Dahl AA, Pripp AH, Michelsen TM. Sexual activity and functioning after risk-reducing salpingo-oophorectomy: Impact of hormone replacement therapy. Gynecol Oncol 2016;140:101-6.
24. Tucker PE, Bulsara MK, Salfinger SG, Tan JJ, Green H, Cohen PA. Prevalence of sexual dysfunction after risk-reducing salpingo-oophorectomy. Gynecol Oncol 2016;140:95-100.
25. Finch A, Narod SA. Quality of life and health status after prophylactic salpingo-oophorectomy in women who carry a BRCA mutation: A review. Maturitas 2011;70:261-5.
26. Fang CY, Cherry C, Devarajan K, Li T, Malick J, Daly MB. A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecol Oncol 2009;112:594-600.
27. Finch A, Metcalfe KA, Chiang JK, Elit L, McLaughlin J, Springate, et al. The impact of prophylactic salpingooophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol Oncol 2011;121:163-8.
28. Finch A, Metcalfe KA, Chiang J, Elit L, McLaughlin J, Springate C, et al. The impact of prophylactic salpingooophorectomy on quality of life and psychological distress in women with a BRCA mutation. Psychooncology 2013;22:212-9.
29. Gallagher JC. Effect of early menopause on bone mineral density and fractures. Menopause 2007;14(3 Pt 2):567-71.
30. Melton LJ, 3rd, Khosla S, Malkasian GD, Achenbach SJ, Oberg AL, Riggs BL. Fracture risk after bilateral oophorectomy in elderly women. J Bone Miner Res 2003;18:900-5.
31. Tuppurainen M, Kröger H, Honkanen R, Puntila E, Huopio J, Saarikoski S, et al. Risks of perimenopausal fractures-a prospective population-based study. Acta Obstet Gynecol Scand 1995;74:624-8.
32. Cohen JV, Chiel L, Boghossian L, Jones M, Stopfer JE, Powers J, et al. Non-cancer endpoints in BRCA 1/2 carriers after risk-reducing salpingo-oophorectomy. Familial Cancer 2012;11:69-75.
33. Garcia C, Lyon L, Conell C, Litteil RD, Powell CB. Osteoporosis risk and management in BRCA1 and BRCA2 carriers who undergo risk-reducing salpingo-oophorectomy. Gynecol Oncol 2015;138:723-6.
34. Challberg J, Ashcroft L, Lalloo F, Eckersley B, Clayton R, Hopwood P, et al. Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. Br J Cancer 2011;105:22-7.
35. Fakkert IE, Abma EM, Westrik IG, Lefrandt JD, Wolffenbuttel BH, Oosterwijk JC, et al. Bone mineral density and fractures after risk-reducing salpingooophorectomy in women at increased risk for breast and ovarian cancer. Eur J Cancer 2015;51:400-8.
36. Khan A, Fortier M; Menopause and Osteoporosis Working Group, Society of Obstetricians and Gynaecologists of Canada. Osteoporosis in menopause. J Obstet Gynaecol Can 2014;36:839-43.
37. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int 2013;24:23-57.
38. de Villiers TJ, Gass ML, Haines CJ, Hall JE, Lobo RA, Pierroz DD, et al. Global consensus Statement on menopausal hormone therapy. Climacteric 2013;16:203-4.
39. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:25-54.
40. Kannel WB, Hjortland MC, McNamara PM, Gordon T. Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 1976;85:447-52.
41. Colditz GA, Willett WC, Stampfer MJ, Rosner B, Speizer FE, Hennekens CH. Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-10.
42. Atsma F, Bartelink ML, Grobbee DE, van der Schouw YT. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause 2006;13:265-79.
43. Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ 3rd. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol 2006;7:821-8.
44. Rivera CM, Grossardt BR, Rhodes DJ, Brown RD Jr, Roger VL, Melton LJ 3rd, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009;16:15-23.
45. Parker WH, Feskanich D, Broder MS, Chang E, Shoupe D, Farquhar CM, et al. Long-term mortality associated with oophorectomy compared with ovarian conservation in the nurses' health study. Obstet Gynecol 2013;121:709-16.
46. Rocca WA, Grossardt B, Miller VM, Shuster LT, Brown RD Jr. Premature menopause or early menopause and risk of ischemic stroke. Menopause 2012;19:272-7.
47. Michelsen TM, Pripp AH, Tonstad S, Trope CG, Dorum A. Metabolic syndrome after risk-reducing salpingooophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study. Eur J Cancer 2009;45:82-9.
48. Michelsen TM, Tonstad S, Pripp AH, Trope CG, Dorum A. Coronary heart disease risk profile in women who underwent salpingo-oophorectomy to prevent hereditary breast ovarian cancer. Int J Gynecol Cancer 2010;20:233-9.
49. Shukla PC, Singh KK, Quan A, Al-Omran M, Teoh H, Lovren F, et al. BRCA1 is an essential regulator of heart function and survival following myocardial infarction. NatCommun 2011;2:593.
50. Singh KK, Shukla PC, Quan A, Al-Omran M, Lovren F, Pan Y, et al. BRCA1 is a novel target to improve endothelial dysfunction and retard atherosclerosis. J Thorac Cardiovasc Surg 2013;146:949-60.e4.
51. Arts-de Jong M, Maas AH, Massuger LF, Hoogerbrugge N, de Hullu JA. BRCA1/2 mutation carriers are potentially at higher cardiovascular risk. Crit Rev Oncol Hematol 2014;91:159-71.
52. Stevenson JC. HRT and the primary prevention of cardiovascular disease. Maturitas 2007;57:31-4.
53. de Villiers TJ, Pines A, Panay N, Gambacciani M, Archer DF, Baber RJ, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316-37.
54. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology 2007;69:1074-83.
55. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al. Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology 2008;70:200-9.
56. Henderson VW, Sherwin BB. Surgical versus natural menopause: cognitive issues. Menopause 2007;14:572-9.
57. Phung TK, Waltoft BL, Laursen TM, Settnes A, Kessing LV, Mortensen PB, et al. Hysterectomy, oophorectomy and risk of dementia: a nationwide historical cohort study. Dement Geriatr Cogn Disord 2010;30:43-50.
58. Erekson EA, Martin DK, Ratner ES. Oophorectomy: the debate between ovarian conservation and elective oophorectomy. Menopause 2013;20:110-4.
59. Genazzani AR, Pluchino N, Luisi S, Luisi M. Estrogen, cognition and female ageing. Hum Reprod Update 2007;13:175-87.
60. Maki PM, Henderson VW. Hormone therapy, dementia, and cognition: the Women's Health Initiative 10 years on. Climacteric 2012;15:256-62.
61. Rocca WA, Grossardt BR, Shuster LT. Oophorectomy, menopause, estrogen treatment, and cognitive aging: clinical evidence for a window of opportunity. Brain Res 2011;1379:188-98.
62. rd. Long-term effects of bilateral oophorectomy on brain aging: unanswered questions from the Mayo Clinic Cohort Study of Oophorectomy and Aging. Womens Health (Lond Engl) 2009;5:39-48.
63. Lehert P, Villaseca P, Hogervorst E, Maki PM, Henderson VW. Individually modifiable risk factors to ameliorate cognitive aging: a systematic review and metaanalysis. Climacteric 2015;18:678-89.
64. Henderson VW. Alzheimer's disease: review of hormone therapy trials and implications for treatment and prevention after menopause. J Steroid Biochem Mol Biol 2014;142:99-106.
65. Reuter-Lorenz PA, Cimprich B. Cognitive function and breast cancer: promise and potential insights from functional brain imaging. Breast Cancer Res Treat 2013;137:33-43.
66. Biglia N, Mariani L, Ponzone R, Sismondi P. Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1-2 mutation carriers. Maturitas 2008;60:71-7.
67. Henderson VW. Three midlife strategies to prevent cognitive impairment due to Alzheimer's disease. Climacteric 2014;17(Suppl 2):38-46.
68. Hoffmann M, Hammar M, Kjellgren Kl, Lindh-Åstrand L, Brynhildsen J. Changes in women's attitudes towards and use of hormone therapy after HERS and WHI. Maturitas 2005;52:11-17.
69. Santen RJ. Menopausal hormone therapy and breast cancer. J Steroid Biochem Mol Biol 2014;142:52-61.
70. Gompel A, Burger H. A Commentary on a recent update of the ovarian cancer risk attributable to menopausal hormone therapy. Climacteric 2015;18:376-8.
71. Gadducci A, Biglia N, Cosió S, Sismondi P, Genazzani AR. Gynaecologic challenging issues in the management of BRCA mutation carriers: oral contraceptives, prophylactic salpingo-oophorectomy and hormone replacement therapy. Gynecol Endocrinol 2010;26:568-77.
72. Marchetti C, Iadarola R, Palaia I, di Donato V, Perniola G, Muzii L, et al. Hormone therapy in oophorectomized BRCA1/2 mutation carriers. Menopause 2014;21:763-8.
73. Rebbeck TR, Friebel T, Wagner T, Lynch HT, Garber JE, Daly MB, et al. Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCAl and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 2005;23:7804-10.
74. Eisen A, Lubinski J, Gronwald J, Moller P, Lynch HT, Klijn J, et al. Hormone therapy and the risk of breast cancer in BRCA 1 mutation carriers. J Natl Cane Inst 2008;100:1361-7.
75. Armstrong K, Schwartz JS, Randall T, Rubin SC, Weber B. Hormone replacement therapy and life expectancy after prophylactic oophorectomy in women with BRCA1/2 mutations: a decision analysis. J Clin Oncol 2004;22:1045-54.
76. Walker JL, Powell CB, Chen LM, Carter J, Bae Jump VL, et al. Society of Gynecologic Oncology recommendations for the prevention of ovarian cancer. Cancer 2015;121:2108-20.
77. Rippy L, Marsden J. Is HRT justified for symptom management in women at higher risk of developing breast cancer? Climacteric 2006;9:404-15.
78. Antoine C, Liebens F, Carly B, Pastijn A, Neusy S, Rozenberg S. Safety of hormone therapy after breast cancer: a qualitative systematic review. Hum Reprod 2007;22:616-22.
79. Biglia N, Bounous VE, Sgro LG, D'Alonzo M, Pecchio S, Nappi RE. Genitourinary syndrome of menopause in breast cancer survivors: are we facing new and safe Hopes? Clin Breast Cancer 2015;15:413-20.
80. Nappi RE, Panay N, Bruyniks N, Castelo-Branco C, De Villiers TJ, Simon JA. The clinical relevance of the effect of ospemifene on symptoms of vulvar and vaginal atrophy. Climacteric 2015;18:233-40.
81. Palacios S, Castelo-Branco C, Currie H, Mijatovic V, Nappi RE, Simon J, et al. Update on management of genitourinary syndrome of menopause: A practical guide. Maturitas 2015;82:308-13.
82. Nappi RE, Palacios S, Panay N, Particco M, Krychman ML. Vulvar and vaginal atrophy in four European countries: evidence from the European REVIVE Survey. Climacteric 2016;19:188-97.
83. Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric 2014;17:1-14.
84. Wurz GT, Soe LH, Degregorio MW. Ospemifene, vulvovaginal atrophy, and breast cancer. Maturitas 2013;74:220-5.
85. Berlin J, Dury AY, Ouellet J, Pelletier G, Labrie F. Localization of the androgen-synthesizing enzymes, androgen receptor, and sex steroids in the vagina: possible implications for the treatment of postmenopausal sexual dysfunction. J Sex Med 2014;11:1949-61.
86. Witherby S, Johnson J, Demers L, Mount S, Littenberg B, Maclean CD, et al. Topical testosterone for breast cancer patients with vaginal atrophy related to aromatase inhibitors: a phase I/II study. Oncologist 2011;16:424-31
87. Labrie F, Archer DF, Koltun W, Vachon A, Young D, Frenette L, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause. Menopause 2016;23:243-56.
88. Casey PM, Faubion SS, MacLaughlin KL, Long ME, Pruthi S. Caring for the breast cancer survivor's health and wellbeing. World J Clin Oncol 2014;5:693-704.
89. Mintziori G, Lambrinoudaki I, Goulis DG, Ceausu I, Depypere H, Erel CT, et al. EMAS position statement: Non-hormonal management of menopausal vasomotor symptoms. Maturitas 2015;81:410-3.
90. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause 2015;22:1155-74.
91. Drewe J, Bucher KA, Zahner C. A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. SpringerPlus 2015;4:65.
92. Simon JA, Portman DJ, Kaunitz AM, Mekonnen H, Kazempour K, Bhaskar S, et al. Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms: two randomized controlled trials. Menopause 2013;20:1027-35.
93. Depypere HT, Comhaire FH. Herbal preparations for the menopause: beyond isoflavones and black cohosh Maturitas 2014;77:191-4.
94. Lethaby A, Marjoribanks J, Kronenberg F, Roberts H, Eden J, Brown J. Phytoestrogens for menopausal vasomotor symptoms. Cochrane Database Syst Rev 2013;12:CD001395.
95. Sinha A, Ewies AA. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric 2013;16:305-12.
96. Salvatore S, Nappi RE, Zerbinati N, Calligaro A, Ferrero S, Origoni M, et al. A 12-week treatment with fractional C02 laser for vulvovaginal atrophy: a pilot study. Climacteric 2014;17:363-9.
97. Gambacciani M, Levancini M, Cervigni M. Vaginal erbium laser: the second-generation fhermofherapy for the genitourinary syndrome of menopause. Climacteric 2015;18:757-63.
98. Martin-Herranz A, Salinas-Hernandez R Vitamin D supplementation review and recommendations for women diagnosed with breast or ovary cancer in the context of bone health and cancer prognosis/risk. Crit Rev Oncol Hematol 2015;96:91-9.
99. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen versus raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of tamoxifen and raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-41.
100. Ingle JN, Liu M, Wickerham DL, Schaid DJ, Wang L, Mushiroda T, et al. Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov 2013;3:812-25.